Table 2.
Clinical manifestations† | LUMINA n = 23 |
Hopkins n = 17 |
APLS n = 17 |
---|---|---|---|
All thrombosis (arterial and/or venous) | 6 (26.1) | 12 (70.6) | 6 (35.3) |
Pregnancy loss/ complications | 3 (13.0) | 9 (52.9) | 1 (5.8) |
Stroke | 1 (4.3) | 4 (23.5) | 2 (11.7) |
Seizure | 1 (4.3) | 6 (35.3) | 0 (0) |
Myocardial infarction | 2 (8.7) | 4 (23.5) | 0 (0) |
Valvular heart disease | 1 (4.3) | 1 (5.8) | 0 (0) |
Pulmonary Arterial hypertension | 0 (0) | 5 (29.4) | 0 (0) |
Skin ulcers | 1 (4.3) | 0 (0) | 0 (0) |
Livedo reticularis | N/A | 3 (17.6) | 0 (0) |
Thrombocytopenia | 5 (21.7) | 7 (41.2) | 2 (11.7) |
ESRD | 0 (0) | 3 (17.6) | 1 (5.8) |
SLAM-R (mean±SD) | 7.30 ± 5.49 | N/A | N/A |
SELENA-SLEDAI (mean±SD) | N/A | 4.04 ± 3.53 | N/A |
Except where indicated otherwise, values are the number (%) of patients.
LUMINA = Lupus in Minorities, Nature versus nurture; APLS = Antiphospholipid Standardization Laboratory; NA = not available; ESRD: end-stage renal disease; SLAM-R: Systemic Lupus Activity Measure, Revised; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.
Includes traditional and non-traditional antiphospholipid syndrome-associated manifestations